Clover and Ascentage Pharma Announce Clinical Collaboration to Evaluate Recombinant Human TRAIL-Trimer Fusion Protein, SCB-313, in Combination with IAP Antagonist, APG-1387 for the Treatment of Peritoneal Carcinomatosis
Summary : Clover Biopharmaceuticals, Ltd. (Clover; Stock Code: 2197.HK), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates and…